Screening for Down’s syndrome

Slides:



Advertisements
Similar presentations
OBSTETRICAL ULTRASOUND
Advertisements

Examples of Sound Screening:
SOUTH AUSTRALIAN MATERNAL SERUM ANTENATAL SCREENING (SAMSAS© ) PROGRAM
Antenatal Screening Dr Emma Parry CMFM
Screening “the systematic application of a test procedure to identify individuals at sufficient risk to warrant diagnostic investigations” CVS 12wks Amniocentesis.
INVERSION OF ANTENATAL PYRAMID
Second-trimester maternal serum screening
Computational Intelligence
Sonographic Detection of Aneuploidy Eric H. Dellinger, MD Director, Division of Maternal-Fetal Medicine Greenville Hospital System Greenville, South Carolina.
Genetics and Primary Care
Prenatal Testing for Down Syndrome: Where Do We Stand Today? David B. Fox, MD Riverside Methodist Hospital.
Prenatal Genetics OG Supplemental Information Drs. Deborah Driscoll and Michael Mennuti.
The New Prenatal Screening Tests
2 cases of congenital abnormality Lent term year 1.
IF FIFTY IS THE NEW FORTY…THEN 1 ST TRIMESTER SCREENING IS THE NEW THIRTY FIVE James Keller MD.
GP Shared Care Maternal screening for adverse pregnancy outcome 14th March 2015 Dr Rosalie Grivell Consultant Obstetrician and Maternal Fetal Medicine.
NON – INVASIVE PRENATAL TESTING
Prenatal Genetic Testing for Chromosomal Anomalies By: Linda DeFranco.
Enhanced Prenatal Screening Program
Biochemical tests and ‘marker chemicals’
IN THE NAME OF GOD. CRITICALLY APPRAISED TOPIC If there is a Non-invasive prenatal testing for aneuploidies with low FPR at first trimester? If we can.
Pregnancy & Newborn Screening Developments
Ultrasound imaging.
Ultrasound in Obstetrics and Gynecology
Max Brinsmead MB BS PhD November  Some 1- 2% of babies will have a major disability that dates from the prenatal period  Either  Chromosomal.
Ultrasound markers of chromosomal abnormalities
Photo: courtesy Travel Alberta.  The provision of information for individuals  Women have the right to access information about the health of their.
Introduction  Preterm birth is the leading cause of perinatal death.  Handicap in children and the vast majority of mortality and morbidity relates.
DR VIDYALEKSHMY R DGO, DNB,MRCOG. CONGENITAL ANOMALIES Real trauma to the family Diagnosed usually after 20 Weeks. 20 Weeks is the upper limit for legal.
First Trimester Screening
Routine Anomaly Scan Ilse Erasmus.
Objectives Goals of the week scanGoals of the week scan Fetal nuchal translucency in the detection of aneuploidyFetal nuchal translucency in.
Ultrasound in obstetrics III By Dr. Khattab KAEO Assis. Prof. of Obstetrics and Gynaecology Faculty of Medicine, Al-Azhar University, Damietta.
First and Early Second Trimester Diagnosis of Fetal Heart Disease 성균관의대 소아과 삼성제일병원 진단방사선과 민 지 연.
In the name of God.
Early Prenatal Screening in Primary Care BC College of Family Physicians 21 st Annual Scientific Assembly Ken Seethram, MD, FRCSC, FACOG Pacific Centre.
產科常見檢查 R 4 蔡曉文. Screening for neural tube defects and Down syndrome Screening: identifies individuals whose risk is high for further evaluation. Screening:
Prenatal Diagnostic Sonography
SMFM Clinical Practice Guidelines
National Women’s Screening for Aneuploidy Dr Emma Parry CMFM Clinical Director Maternal-Fetal Medicine National Women’s Health.
In the name of god First Trimester Screening Dr.M.Moradi.
Prenatal Diagnosis of Congenital Malformations for Undergraduates
VI. Hrvatski kongres o ginekološkoj endokrinologiji, humanoj reprodukciji i menopavzi s međunarodnim sudjelovanjem , Brijuni DARIJA STRAH.
In the name of god.
Vajiheh Marsoosi, M.D Associate Professor of TUMS Shariati Hospital.
The New Prenatal Screening Tests Langley Memorial Hospital Grand Rounds November 8, 2007 Ken Seethram, MD, FRCSC, FACOG Obstetrics and Gynecology, Burnaby.
The Role of Prenatal screening as part of Routine Obstetric Care
Conceptual & technical advances in Down’s syndrome screening Howard Cuckle
HIGHER HUMAN BIOLOGY Unit 2 Physiology and Health 1. Ante-natal Screening.
Nuchal Translucency (NT) Screen Ernest F. Talarico, Jr., Ph.D. Associate Director of Medical Education Associate Professor of Anatomy & Cell Biology Associate.
Erika Castro, PGY 3 Cook County-Loyola-Provident Family Medicine Residency 2/27/2014 PRENATAL SCREENING AND DIAGNOSIS COUNSELING
Dr Shuhaila Ahmad Associate Professor FetoMaternal Unit UKMMC.
Definition & Risk Factors of FGR FGR, also called IUGR is the term used to describe a fetus that has not reached its growth potential because of genetic.
Genetic Testing in Pregnancy Lisbeth M. Lazaron, MD March 2013.
Genetic Counseling and Prenatal Diagnosis Dr. Hassan Nasrat FRCS & FRCOG Professor Dept. Obstetrics & Gynecology King Abdulaziz University Hospital.
UOG Journal Club: July 2013 Implementation of maternal blood cell-free DNA testing in early screening for aneuploidies M. M. Gil, M. S. Quezada, B. Bregant,
Prenatal Screening and Diagnosis. What is Prenatal Diagnosis?  In-utero detection of fetal anomalies General population risk is 3-5% for any birth defect.
سونوگرافی سه ماهه دوم و Soft Markers
UOG Journal Club: March 2016
Antenatal Screening Rebecca Sykes.
Aneuploidy and NTD screening
Jeffrey A. Kuller, MD; Sean C. Blackwell, MD
UOG Journal Club: July 2012 Maternal hemodynamics at 11–13 weeks’ gestation and risk of pre-eclampsia A. Khalil, R. Akolekar, A. Syngelaki, M. Elkhouli.
غربالگری ناهنجاریهای جنین
Objectives Goals of the week scan
Prenatal Screening for Genetic Conditions
guidance on antenatal screening
Ultrasound in fetal screening ( Down syndrome,…)
NON – INVASIVE PRENATAL TESTING
IN THE NAME OF GOD First trimester screening for aneuploidy
Presentation transcript:

Screening for Down’s syndrome FAQ’s Dr Sheila Balakrishnan MD DNB FRCOG FICOG Prof in OBGYN Medical College Trivandrum

Do you think screening for Down’s is necessary and if so for what age group?

What is meant by ‘apriori risk’?

A woman’s risk of having a fetus with trisomy 21 depends on her age, gestational age and her history of chromosomal defects In general we mean the age related risk at term

Age Midtrimester Term 35 1 in 384 1 in 250 40 1 in 106 1 in 70

Best method of screening as of today?

First trimester screening by the combined test- NT PAPP A and β hCG- is added to the apriori risk

What is NT?

USS term for the physiologic collection of fluid underneath the nuchal skin extending for a variable distance over the fetal head and back at 11-14 weeks For unclear reasons this collection is unduly sensitive to fetal problems

Who described NT and in which year?

Kypros Nicolaides in 1992

What are the requirements of a good NT?

The maximum thickness of the subcutaneous translucent area between the skin and soft tissue that overlies the fetal spine in the sagittal plane

11 weeks – 13 weeks 6 days CRL 45- 84 mm Mid sagittal view Neutral position of head Magnification (>70%) Widest part of translucency to be measured Frontal process of maxillary bone should not be seen Amnion must be seen separate Biggest of 3 measurements

What other markers can be added to NT in the scan to increase detection rate?

Increases detection rate to 95% and decreases false pos rate to 2% Nasal bone (fallacy – nasal skin) Ductus venosus (absent or reversed flow) Tricuspid regurgitation Increases detection rate to 95% and decreases false pos rate to 2% FMF angle >85° (b/w the upper surface of upper palate and frontal bone in midsagittal view) The more the markers the more error can occur

73% Downs absent nasal bone 0.5% normal

A 11-14 weeks scan reports an NT of 1.2 mm. What does it imply?

Not useful and action should not be taken on basis of absolute values usually All values are to be expressed as MOM Special software available Standardisation is by the FMF which provides certification

Are there any absolute cut offs for NT and the other tests?

NT >3.5 mm falls above 95th centile for any week bw 11-14 vweeks PAPP A <0.5 MOM(think of IUGR) β hCG >2.5 MOM These values justify invasive testing in themselves

What is the detection rate with the combined test?

85-90% for a false pos rate of 5% Amniocentesis rate is about 5% Adding nasal bone may increase the detection rate to 90% If NT alone – 77%

Other methods available?

Second trimester screening by triple and quadruple test Integrated test Sequential test Contingent test In all these amniocentesis rate is higher (about 8%)

Method First trimester screening Triple test Quadruple test Integrated test Sequential test Components NT, β hCG and MSAFP MSAFP, β hCG and uE3 MSAFP, β hCG, uE3 & Inhibin First trimester screen & Quadruple test Detection rate 85% 70% 95% 90%

What is the contingent test?

FTS is offered and depending upon results women are divided into three groups High risk- invasive procedure Low risk- reassurance Intermediate risk- offer second trimester serum screening and invasive testing

What is the genetic sonogram?

Soft tissue markers of aneuploidy Nuchal skin fold thickness Absent or hypoplastic nasal bone (7) Ventriculomegaly Aberrant right subclavian artery Renal pyelectasis Choroid plexus cysts Hyperechoic bowel Short femur Echigenic focus in heart Structural anomalies like duodenal atresia

What will you recommend in the foll situations 1 Choroid plexus cysts 2 Increased NSFT in second trimester scan

Presence of one such marker should promote a detailed search for other markers and if more than one is present, invasive testing can be recommended One marker like NSFT, nasal bone or a structural anomaly may be an indication for amniocentesis

Which structural anomalies are definite indications for karyotyping?

Duodenal atresia Omphalocoele AV canal defects

Thick NT and normal KT, what next ?

Cardiac anomalies Structural defects like omphalocoele Predictor of TTTS in multiple pregnancies Inspite of everything a fetal loss of 4% is reported- COUNSEL

11-13 week scan Uterine artery PI FMF Certificate of competence in measurement of uterine artery PI The Fetal Medicine Foundation has now established software for the calculation of risk for preeclampsia. The software is provided free of charge to those who comply with the FMF regulation of NT screening and have demonstrated competence in the Doppler assessment of the uterine arteries at the 11-13 weeks scan.

FMF screening for PE Established software for prediction of PE Uterine artery PI + maternal history, BP, Papp A and PlGF Risk calculated for early and late PE Detects 90% of early onset PE and 45% late PE for a false pos rate of 10%

Thank you